Corvus Pharmaceuticals Financial Ratios
NASDAQ: CRVSHealth CareBiotechnology: Pharmaceutical PreparationsUSD
10.52+0.31 (+3.04%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Corvus Pharmaceuticals ratio analysis
Return on equity reached -25.0%, meaning Corvus Pharmaceuticals generated -0.25 dollars of profit for every dollar of shareholders' equity. Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.
Summary generated from market data by MetaCap's automated system. Methodology
Corvus Pharmaceuticals financial ratios (annual)
| Ratio | FY 2025 | FY 2024 | FY 2023 | FY 2021 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Price / book | 9.44 | 10.92 | 2.18 | 0.71 | 1.04 | 1.45 | 1.94 | 1.08 | 2.50 | 1.66 |
| Return on equity (ROE) | -25.0% | -191.3% | -69.9% | -73.6% | -44.5% | -8.3% | -65.6% | -42.5% | -65.6% | -27.4% |
| Return on assets (ROA) | -21.5% | -90.4% | -59.3% | -60.5% | -39.5% | -7.0% | -55.8% | -39.7% | -58.7% | -26.0% |
| Current ratio | 6.21 | 1.54 | 4.07 | 4.06 | 7.36 | 3.73 | 7.76 | 16.45 | 10.17 | 22.89 |